Articles related to ALERTS/WARNINGS/ADVISEMENT

With a significant rise in meningococcal disease cases in 2023 and continuing into 2024, physicians must be alert for non-traditional symptoms such as septic arthritis and bacteremia to ensure timely and effective patient management.

The FDA’s recent warnings about high-concentration lidocaine in OTC analgesics spotlight a significant health risk, emphasizing the need for healthcare professionals to guide patients in choosing safe and approved pain relief options.

The FDA has issued an alert to healthcare providers to ensure the correct volume of the Moderna COVID-19 vaccine is withdrawn from the vial for children aged six months to 11 years. This comes amid reports of double doses being administered to children, emphasizing the importance of precise dosage in vaccine administration.

The FDA’s recent warning about compounded ketamine products underscores the need for rigorous clinical studies to investigate ketamine’s benefit-risk profile and safe-use conditions in the treatment of psychiatric disorders.

Stay abreast of the latest developments in patient care. Learn more about the FDA’s recent warning on the potential risks associated with compounded ketamine products used for treating psychiatric disorders.

FDA Cautions Against Hidden Drug Ingredients in Joint Pain Supplements In response to recent findings, the FDA warns of significant health risks associated with three specific dietary supplements marketed for joint pain and rheumatoid arthritis relief due to the discovery of unlisted active pharmaceutical ingredients.